CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $17,830
- in 3 filings, $18K under 10b5-1 plans
Net −$17,830. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-24 | Regnante Keith CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2026-02-18 | Regnante Keith CHIEF FINANCIAL OFFICER | Sale | −4,739 | $16.35 | $77K | 39,261 |
| 2025-02-18 | Regnante Keith CHIEF FINANCIAL OFFICER | Grant or award | +44,000 | 44,000 | ||
| 2024-02-13 | Regnante Keith CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2024-01-04 | Regnante Keith CHIEF FINANCIAL OFFICER | Exercise or conversion | +40,000 | $16.00 | $640K | 40,000 |
| 2024-01-04 | Regnante Keith CHIEF FINANCIAL OFFICER | Sale | −40,000 | $45.29 | $1.8M | 0 |
| 2024-01-04 | Regnante Keith Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −40,000 | 53,622 | ||
| 2023-11-04 | Regnante Keith Chief Financial Officer | Exercise or conversion | +40,000 | $16.00 | $640K | 40,000 |
| 2023-11-04 | Regnante Keith Chief Financial Officer | Sale | −40,000 | $45.29 | $1.8M | 0 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Exercise or conversion 10b5-1 | +20,000 | $16.00 | $320K | 20,000 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −15,993 | $45.03 | $720K | 4,007 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −1,428 | $46.46 | $66K | 2,579 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −2,579 | $47.25 | $122K | 0 |
| 2023-06-09 | Regnante Keith Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −20,000 | 93,622 | ||
| 2023-06-08 | Regnante Keith Chief Financial Officer | Exercise or conversion 10b5-1 | +20,000 | $16.00 | $320K | 20,000 |
| 2023-06-08 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −17,301 | $47.66 | $825K | 2,699 |
| 2023-06-08 | Regnante Keith Chief Financial Officer | Sale 10b5-1 | −2,699 | $48.65 | $131K | 0 |
| 2023-06-08 | Regnante Keith Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) 10b5-1 | −20,000 | 113,622 | ||
| 2023-02-16 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-01-21 | Regnante Keith Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 |
Page 1 of 2 · 23 trades